BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Lundbeck Inc. 

Four Parkway North
Suite 200
Deerfield  Illinois  60015  U.S.A.
Phone: 800-455-1141 Fax: 847-282-1001


SEARCH JOBS
Lundbeck Inc. - Making a Difference One Patient at a Time

Headquartered in Deerfield, Illinois, with a portfolio of 17 specialty therapies and a pipeline of promising central nervous system (CNS) drugs, Lundbeck Inc. is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available.

As a wholly-owned subsidiary of H. Lundbeck A/S of Denmark, Lundbeck Inc. has a unique ownership structure. The company is 70 percent owned by the Lundbeck Foundation, which contributes millions annually to scientific research. In 2009, the Foundation granted more than $58 million to support research in biomedical and natural sciences.

Lundbeck Inc. offers the chance to make a difference while working in a unique and innovative environment. We are united by our passion and responsibility for helping the people with unmet medical needs. In addition to our extensive CNS pipeline that addresses a range of disorders from Alzheimer’s disease to Parkinson’s disease and depression, Lundbeck focuses on rare diseases with five orphan-designated therapies on the market and one more in late-stage development.

Our team of 350 pharmaceutical professionals, including an experienced team of clinical, regulatory and commercial experts, has a proven track record of working effectively with the U.S. Food and Drug Administration, developing and marketing high-need drugs that improve patients’ lives, and quickly and cost effectively bringing new products to market. Our operational excellence, diverse commercial portfolio and compelling development pipeline puts us in an excellent position for continued innovation and growth that will benefit patients for years to come.

At Lundbeck you can make a difference one patient at a time. If you wish to join a team where the challenges are great, the mission is meaningful and you can directly see the results of your hard work, Lundbeck may be the place for you.


 Key Statistics


Email: contact@lundbeck.com
Ownership: Public

Web Site: Lundbeck Inc.
Employees:
Symbol: LUN.CO
 









 Company News
EU to Fine Lundbeck Inc. (LUN.CO), Others for Blocking Generic Drugs 6/4/2013 7:37:57 AM    More...
Takeda Pharmaceuticals and Lundbeck Inc. (LUN.CO) Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, an Investigational Compound for Major Depressive Disorder 5/20/2013 10:04:12 AM    More...
Lundbeck Inc. (LUN.CO) Release: Vortioxetine Clinical Phase III Data Show Significant Improvement in Symptoms of Major Depression 5/20/2013 10:00:40 AM    More...
Lundbeck Inc. (LUN.CO) Increases its Share Capital by 9,772 Shares (0.005% of Outstanding Shares) as a Result of Employee Warrant Exercise 5/16/2013 9:43:31 AM    More...
Lundbeck Inc. (LUN.CO) Announces Positive Results for Brintellix™ (Vortioxetine) in Adult Patients With Major Depression and Inadequate Response to SSRI or SNRI Therapy 4/8/2013 11:37:26 AM    More...
Lundbeck Inc. (LUN.CO) Presents New Data on Selincro From Three Phase III Studies That Consistently Show a Significant Reduction in Alcohol Consumption in Alcohol Dependent Patients With High Risk Drinking Level 4/8/2013 11:35:12 AM    More...
Lundbeck Inc. (LUN.CO) Given EU Nod for Alcohol Dependence Drug 2/28/2013 8:05:36 AM    More...
Otsuka Pharmaceutical Co., Ltd. and Lundbeck Inc. (LUN.CO) Initiate the Regulatory Process for Aripiprazole (Once-Monthly) Depot Formulation in Europe 12/27/2012 9:40:22 AM    More...
Lundbeck Inc. (LUN.CO) Anticipates New Drug "Feast" 12/6/2012 8:28:23 AM    More...
Lundbeck Inc. (LUN.CO) Opens New Drug Plant in Tianjin 11/12/2012 7:10:11 AM    More...
12345678910...